Table 3 Published outcomes for adolescent patients with HL

From: Outcome of a risk-related therapeutic strategy used prospectively in a population-based study of Hodgkin's lymphoma in adolescents

Authors

Publication year

Number of patients

Ages (years)

Median age (years)

Stages

NLPHL included

Median F/U (month)

CR rate

5 year OS

5 year EFS

Study type

Clarke et al

2001

5630

15–44

NS

NS

Yes

53

NS

NS

5 year DFS 90%

Retrospective, population based

Donaldson and Link

1987

55

1.5–15

10

All

Yes

90

93%

89% at 15 years

5 year RFS 90%

Prospective, observational

Donaldson et al

2002

110

3–20

13

All

Yes

67

100%

99%

93%

Prospective, observational, focused on LR disease

Ekert et al

1988

53

3–16

10

All

Yes

45

96%

94%

92%

Prospective observational

Foltz et al

2006

259

16–21

19

All

Yes

102

97%

91%

10 year PFS 77%

Prospective observational

Friedmann et al

2002

56

8–18

15

All (only HR I–II)

Yes

108

94%

82%

68%

Prospective, observational, focused on HR disease

Hudson et al

1993

85

4–20

14

IIA–IVB

Yes

49

98%

93%

5 year DFS 93%

Prospective, observational, focused on HR disease

Hudson et al

2004

159

2–19

15

All (only HR I–II)

Yes

70

NS

93%

76%

Prospective, observational, focused on HR disease

Hunger et al

1994

57

<18

12

All

Yes

80

100%

96%

93%

Prospective, observational

Hutchinson et al

1998

111

<21

NS

III/IV only

Yes

74

NS

87% at 4 years

82% at 4 years

RCT, focused on HR disease

Jenkin et al

1982

110

<16

NS

All

Yes

70

NS

92%

RFS 68%

Prospective, observational

Jones et al

Present paper 2007

55

13–19

16

All

Yes

107

93%

91%

NS

Prospective, population-based

Landman-Parker et al

2000

202

3–18

12

I/II only

No

74

NS

98%

91%

Prospective, observational, risk-adapted approach

Nachman et al

2002

829

<21

NS

All

Yes

NA

83%

95% at 3 years

87% at 3 years

RCT for patients in CR after chemotherapy

Oguz et al

2005

65

2–15

7

All

Yes

73

95%

96%

91%

Prospective, observational

Schellong et al

1999

578

2–17

13

All

Yes

61

NS

98%

91%

Prospective, observational

Shanker et al

1998

54

2–19

10

All

Yes

66

76%

Stage I–III 93%

Stage IV 44%

 

Prospective, observational

Smith et al

2003

328

2–20

14

All

Yes

59

NS

93%

DFS at 5 years 83%

Prospective, observational using risk-adapted protocols

Weiner et al

1997

179

4–20

13

⩾IIB

Yes

NS

90%

92%

79%

RCT focused on HR disease

Yung et al

2004

210

15–17

16

All

Yes

199

76%

81%

50%

Retrospective, observational

  1. Abbreviations: CR, complete remission; DFS, disease-free survival; EFS, event-free survival; HL, Hodgkin's lymphoma; HR, high risk; LR, low risk. NA, not available; NLPHL, nodular lymphocyte-predominant Hodgkin's lymphoma; NS, non-significant; OS, overall survival; RCT, randomised controlled trial.
Back to article page